Clearmind Medicine
CMND | NASDAQ
$4.18
-$0.35 (-7.73%)
At close: Nov 16, 2026, 4:00 PM ET
$4.00
-$0.18 (-4.31%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Clearmind Medicine Company Profile
Company profile explainedCompany Profile
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.
Key Executives
| Name | Position |
|---|---|
| Adi Zuloff-Shani | Chief Executive Officer |
| Alan Mark Rootenberg | Chief Financial Officer |
| Adi Varon | Controller |
| Mark Haden | Vice President of Business Development |
| Mary-Elizabeth Gifford | Chief of Global Impact |
| Mylene Touboul | Accounting Manager |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 27, 2026 | 6-K | Filing |
| Oct 16, 2026 | 6-K | Filing |
| Oct 13, 2026 | 6-K | Filing |
| Oct 08, 2026 | 6-K | Filing |
| Oct 07, 2026 | 6-K | Filing |
| Sep 30, 2026 | 6-K | Filing |
| Sep 23, 2026 | 6-K | Filing |
| Sep 17, 2026 | 6-K | Filing |
| Sep 14, 2026 | 6-K | Filing |
Clearmind Medicine
| Country | Canada |
| IPO Date | Nov 15, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Adi Zuloff-Shani |
Contact Details
1220 West 6th Avenue Vancouver,
BC V6H 1A5 Canada
Stock Details
| Ticker Symbol | CMND |
| Exchange | NASDAQ |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| CIK Code | 0001892500 |
| CUSIP Number | 185053709 |
| ISIN Number | CA1850537095 |
| SIC Code | 2834 |
Recent News
- 1 month ago / globenewswire.comClearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
- 1 month ago / globenewswire.comClearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
- 2 months ago / thenewswire.comNeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
- 2 months ago / globenewswire.comClearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
- 2 months ago / thenewswire.comStickit Technologies Announces Corporate Update: Leadership Appointments, Capital Restructuring & Loan Acquisition, And Update Of Intellectual Property Portfolio
- 2 months ago / globenewswire.comClearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
- 2 months ago / globenewswire.comClearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
- 2 months ago / globenewswire.comClearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results
- 2 months ago / benzinga.comClearmind Medicine Stock Slides Friday: What's Happening?
- 2 months ago / globenewswire.comClearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
Add to Watchlist
Select watchlists to add or remove CMND